Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.72 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.72 |
| ▸ | CNR1 | P21554 | 9/20 | 0.68 |
| ▸ | CNR2 | P34972 | 8/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.62 |
| ▸ | CASR | P41180 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26262860 | 0.86 | MTNR1A (0.57) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL2427167 | 0.84 | CNR1 (0.70) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL9274180 | 0.82 | ASAH1 (0.63) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL1321256 | 0.82 | CNR1 (0.68) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL4219824 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL11196501 | 0.81 | MTNR1A (0.52) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL2726416 | 0.81 | MTNR1A (0.72) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL7823738 | 0.81 | CNR1 (0.66) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL5468000 | 0.79 | CNR1 (0.64) | MTNR1AMTNR1BCNR1CNR2EPHX2 | |
| SCHEMBL8248986 | 0.79 | CNR1 (0.72) | MTNR1AMTNR1BCNR1CNR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173618-A1 | CYCLIC GD (III) COMPLEX, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 国科温州研究院(温州生物材料与工程研究所) | 2023-09-21 | — | — | WO | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | Prism BioLab Co., Ltd. (JP) | 2015-12-31 | — | — | US | disclosed |
| US-9126981-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | PRISM BIOLAB CORPORATION (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CORPORATION (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088770-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | MTNR1A 779/4885MTNR1B 1504/4885CNR1 4323/4885 |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | MTNR1A 4619/4885MTNR1B 4361/4885CNR1 2227/4885 |
| US-20150376204-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MTNR1A 1991/4885MTNR1B 2916/4885CNR1 2774/4885 |
| US-20140221657-A1 | ALPHA HELIX MIMETIC COMPOSITIONS FOR TREATING CANCER AND OTHER CBP/CATENIN-MEDIATED DISEASES AND CONDITIONS | CREBBP, CTNNB1, CTNNA1 | MTNR1A 1991/4885MTNR1B 2916/4885CNR1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.